Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.

Rickert RC.

Nat Rev Immunol. 2013 Aug;13(8):578-91. doi: 10.1038/nri3487. Review. Erratum in: Nat Rev Immunol. 2013 Sep;13(9):701.

PMID:
23883968
2.

Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.

Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber TG, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, Loh ML, Jung JU, Coligan JE, Bolland S, Mak TW, Limnander A, Jumaa H, Reth M, Weiss A, Lowell CA, Müschen M.

Nature. 2015 May 21;521(7552):357-61. doi: 10.1038/nature14231. Epub 2015 Mar 23. Erratum in: Nature. 2016 Jun 2;534(7605):138.

3.

ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells.

Gobessi S, Laurenti L, Longo PG, Sica S, Leone G, Efremov DG.

Blood. 2007 Mar 1;109(5):2032-9. Epub 2006 Oct 12.

4.

Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.

Köhrer S, Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, Ten Hacken E, Jäger U, Vanura K, O'Brien S, Thomas DA, Kantarjian H, Ghosh D, Wang Z, Zhang M, Ma W, Jumaa H, Debatin KM, Müschen M, Meyer LH, Davis RE, Burger JA.

Leukemia. 2016 Jun;30(6):1246-54. doi: 10.1038/leu.2016.9. Epub 2016 Feb 5.

5.

B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.

Seda V, Mraz M.

Eur J Haematol. 2015 Mar;94(3):193-205. doi: 10.1111/ejh.12427. Epub 2014 Sep 13. Review.

PMID:
25080849
6.

Targeting the B-cell receptor signaling pathway in B lymphoid malignancies.

Buchner M, Müschen M.

Curr Opin Hematol. 2014 Jul;21(4):341-9. doi: 10.1097/MOH.0000000000000048. Review.

7.

B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies.

Puri KD, Di Paolo JA, Gold MR.

Int Rev Immunol. 2013 Aug;32(4):397-427. doi: 10.3109/08830185.2013.818140. Review.

PMID:
23886342
8.

BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.

Robak T, Robak P.

Int Rev Immunol. 2013 Aug;32(4):358-76. doi: 10.3109/08830185.2013.786711. Epub 2013 Apr 25. Review.

PMID:
23617253
9.

Bruton tyrosine kinase (BTK) and its role in B-cell malignancy.

Buggy JJ, Elias L.

Int Rev Immunol. 2012 Apr;31(2):119-32. doi: 10.3109/08830185.2012.664797. Review. Erratum in: Int Rev Immunol. 2012 Oct;31(5):428.

PMID:
22449073
10.

Autoinhibition and adapter function of Syk.

Kulathu Y, Grothe G, Reth M.

Immunol Rev. 2009 Nov;232(1):286-99. doi: 10.1111/j.1600-065X.2009.00837.x. Review.

PMID:
19909371
11.

Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt.

Craxton A, Jiang A, Kurosaki T, Clark EA.

J Biol Chem. 1999 Oct 22;274(43):30644-50.

12.

Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.

McCaig AM, Cosimo E, Leach MT, Michie AM.

Br J Haematol. 2011 Apr;153(2):199-211. doi: 10.1111/j.1365-2141.2010.08507.x. Epub 2011 Feb 24.

PMID:
21352196
13.

Atypical B cell receptor signaling: straddling immune diseases and cancer.

Faris M.

Int Rev Immunol. 2013 Aug;32(4):355-7. doi: 10.3109/08830185.2013.817248. Epub 2013 Jul 12.

PMID:
23848467
14.

Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.

Bernard S, Danglade D, Gardano L, Laguillier C, Lazarian G, Roger C, Thieblemont C, Marzec J, Gribben J, Cymbalista F, Varin-Blank N, Ledoux D, Baran-Marszak F.

Int J Cancer. 2015 Jun 15;136(12):2761-74. doi: 10.1002/ijc.29326. Epub 2014 Dec 3.

15.

Targeting the B cell receptor pathway in chronic lymphocytic leukemia.

Davids MS, Brown JR.

Leuk Lymphoma. 2012 Dec;53(12):2362-70. doi: 10.3109/10428194.2012.695781. Review.

16.

Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape.

Burger JA.

Curr Opin Oncol. 2012 Nov;24(6):643-9. doi: 10.1097/CCO.0b013e3283589950. Review.

PMID:
22960555
17.

Syk mediates BCR- and CD40-signaling integration during B cell activation.

Ying H, Li Z, Yang L, Zhang J.

Immunobiology. 2011 May;216(5):566-70. doi: 10.1016/j.imbio.2010.09.016. Epub 2010 Oct 7.

18.

Cross-linking of B cell antigen receptor-related structure of pre-B cell lines induces tyrosine phosphorylation of p85 and p110 subunits and activation of phosphatidylinositol 3-kinase.

Kuwahara K, Kawai T, Mitsuyoshi S, Matsuo Y, Kikuchi H, Imajoh-Ohmi S, Hashimoto E, Inui S, Cooper MD, Sakaguchi N.

Int Immunol. 1996 Aug;8(8):1273-85.

PMID:
8918697
19.

The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.

Sivina M, Kreitman RJ, Arons E, Ravandi F, Burger JA.

Br J Haematol. 2014 Jul;166(2):177-88. doi: 10.1111/bjh.12867. Epub 2014 Apr 2.

Supplemental Content

Support Center